Jardiance Cost in Minnesota 2026: Prices, Insurance, Medicaid, and Compounded Empagliflozin

What Does Jardiance Actually Cost in Minnesota in 2026?

The manufacturer list price for Jardiance in Minnesota sits at approximately $680 per month for a 30-tablet supply of either the 10 mg or 25 mg dose, and that figure has not changed materially from 2025 [1]. Cash-pay patients without any discount will pay close to that amount at major Minnesota chains including CVS, Walgreens, and Hy-Vee. GoodRx and similar coupon aggregators may pull the out-of-pocket cost down to roughly $550 to $600 at select pharmacies, though prices shift weekly and vary by zip code.

Boehringer Ingelheim and Eli Lilly co-market Jardiance and set its Wholesale Acquisition Cost (WAC). The FDA label confirms the 10 mg and 25 mg tablet formulations [2]. Because no generic empagliflozin tablet has received FDA approval as of mid-2025, brand competition is absent at the retail counter [3].

For context, the EMPA-REG OUTCOME trial demonstrated that empagliflozin 10 mg reduced the composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke by 14% (HR 0.86 to 95% CI 0.74 to 0.99, P<0.001 for noninferiority; P=0.04 for superiority) compared with placebo in 7,020 adults with type 2 diabetes and established cardiovascular disease [4]. That cardiovascular mortality benefit is a primary reason physicians and payers prioritize access to this drug despite its cost.

The American Diabetes Association 2024 Standards of Care recommend SGLT2 inhibitors with proven cardiovascular benefit for patients with type 2 diabetes and atherosclerotic cardiovascular disease, heart failure, or CKD, independent of HbA1c [5]. Minnesota prescribers therefore face real pressure to secure coverage for patients who medically need the drug.

How Minnesota Medicaid Covers Jardiance

Minnesota Medicaid (Medical Assistance) covers Jardiance, but requires prior authorization in every indication: type 2 diabetes, heart failure, and chronic kidney disease [6]. PA approval typically demands chart documentation of the confirmed diagnosis, current HbA1c or eGFR values, and a record showing that at least one preferred agent was trialed first (commonly metformin for diabetes or a loop diuretic for heart failure).

Approval timelines average 3 to 5 business days for standard PA and 24 to 72 hours for expedited medical necessity requests. Minnesota's fee-for-service Medicaid preferred drug list places empagliflozin in a "non-preferred with PA" tier, meaning the co-pay after approval is nominal for most enrollees, often $1 to $3 per fill [7].

MinnesotaCare, the state's subsidized plan for adults above Medicaid income thresholds, follows similar PA requirements. Managed care organizations that contract with the Minnesota Department of Human Services, including UCare, Hennepin Health, and Blue Plus, each maintain their own formulary tiers; PA criteria are aligned with state guidelines but may include additional step-therapy requirements.

Physicians or telehealth providers submitting a PA should include the most recent visit note, lab results (HbA1c for diabetes indications, eGFR and urine albumin-to-creatinine ratio for CKD), and a brief clinical justification citing guideline support. The EMPEROR-Reduced trial (N=3,730) showed empagliflozin reduced the risk of cardiovascular death or hospitalization for heart failure by 25% (HR 0.75 to 95% CI 0.65 to 0.86, P<0.001) in patients with HFrEF [8], and that citation strengthens PA submissions for heart failure indications. Similarly, the EMPEROR-Preserved trial (N=5,988) found empagliflozin reduced first and recurrent hospitalizations for heart failure by 27% in HFpEF patients (HR 0.73 to 95% CI 0.61 to 0.88) [9].

For CKD, the EMPA-KIDNEY trial (N=6,609) showed empagliflozin reduced the risk of kidney disease progression or cardiovascular death by 28% (HR 0.72 to 95% CI 0.64 to 0.82, P<0.001) [10]. Including this reference in a CKD-related PA request is advisable.

Which Commercial Insurance Plans in Minnesota Cover Jardiance?

Most large commercial plans operating in Minnesota cover Jardiance, though placement on formulary tiers varies considerably. Blue Cross Blue Shield of Minnesota, HealthPartners, Medica, and PreferredOne generally place empagliflozin on Tier 3 (preferred brand) with monthly co-pays between $50 and $150 after deductible, depending on plan design [11].

High-deductible health plans present a different problem. A patient on a $3,000 deductible plan pays the full negotiated rate, which may be $580 to $640 per month, until the deductible resets. After the deductible, a Tier 3 co-pay of $75 per month is common.

Medicare Part D plans sold in Minnesota are not eligible for manufacturer savings cards (federal law prohibits this for government-insured beneficiaries). The Inflation Reduction Act, signed into law in August 2022, caps Medicare Part D out-of-pocket drug costs at $2,000 per year starting in 2025 [12]. For a Medicare patient taking Jardiance, that cap represents a meaningful improvement over prior cost-sharing structures.

Employers self-insured under ERISA can design benefit structures that exclude specific drug classes; checking the specific plan's Summary of Benefits and Coverage document is the only reliable way to confirm coverage before a prescription is sent.

The Boehringer Ingelheim / Lilly Savings Card for Minnesota Patients

Commercially insured patients in Minnesota who do not have federal or state government insurance may apply for the Jardiance savings card through Boehringer Ingelheim's patient support program. Eligible patients may pay as little as $10 per month, with the manufacturer covering the remainder up to a defined annual maximum [13].

Eligibility criteria as of 2026:

• Must have commercial insurance that covers Jardiance (the card covers the co-pay gap, not the full drug price for uninsured patients)
• Must be a U.S. resident aged 18 or older
• Must not be enrolled in any federal or state government insurance program, including Medicare, Medicaid, CHIP, or Veterans Affairs benefits

The application process takes roughly 5 minutes online at the Boehringer Ingelheim patient support portal. The card is typically activated within 24 hours and can be presented at any participating Minnesota retail pharmacy. Patients should confirm that their specific pharmacy accepts the card before submitting their first prescription; most major chains participate.

Uninsured patients do not receive the $10 rate under the standard savings card. Boehringer Ingelheim's separate patient assistance program (PAP) may provide Jardiance at no cost for qualifying low-income uninsured patients; income thresholds are reviewed annually and generally align with 400% of the federal poverty level [14].

Compounded Empagliflozin in Minnesota: What Is Legal and What Does It Cost?

Compounded empagliflozin is legally available in Minnesota through state-licensed 503A compounding pharmacies. A 503A pharmacy compounds medications for individual patients based on a valid prescription from a licensed prescriber. The pharmacy must hold an active Minnesota Board of Pharmacy license and comply with United States Pharmacopeia standards for non-sterile compounding [15].

Key distinctions Minnesota patients should understand:

503A pharmacies operate patient-specific. Each batch is prepared for a named individual after a prescription is received. These pharmacies are regulated primarily by the Minnesota Board of Pharmacy, with FDA oversight applying when ingredients cross state lines. Compounded empagliflozin from a 503A source is legal in Minnesota provided the pharmacy holds a valid state license and the prescriber issues a valid, individualized prescription.

503B outsourcing facilities produce larger batches for healthcare facilities, generally without patient-specific prescriptions. Empagliflozin is not on FDA's current 503B bulk drug substance list, meaning 503B compounding of empagliflozin for office-stock use is not federally authorized at this time [16].

Pricing at 503A pharmacies varies. Some telehealth platforms that operate in Minnesota price compounded empagliflozin at $0 to $150 per month, depending on their specific business model and whether a membership or consultation fee is bundled. The cost difference versus the $680 brand list price is substantial.

Patients should ask any compounding pharmacy for a Certificate of Analysis confirming that the active pharmaceutical ingredient (API) meets purity standards. The API should originate from an FDA-registered supplier. This verification step distinguishes legitimate 503A compounding from lower-quality operations.

Minnesota prescribers writing for compounded empagliflozin should note that the compounded product has no FDA-approved labeling. The prescriber assumes responsibility for selecting a dose and formulation based on clinical judgment and available evidence. Standard doses used in compounded formulations typically mirror the FDA-approved 10 mg or 25 mg daily doses studied in the trials above.

The FDA issued a draft guidance in 2023 clarifying that compounding of drugs that are essentially copies of commercially available products may face additional scrutiny [17]. Empagliflozin falls into a gray area because the brand product is commercially available, and prescribers should document a clinical rationale (typically, cost and access) in the patient record.

Telehealth Prescribing of Jardiance in Minnesota

Telehealth prescribing of Jardiance is permitted in Minnesota. A licensed prescriber, including physicians, nurse practitioners, and physician assistants operating under appropriate supervision agreements, may evaluate a patient via synchronous audio-video telehealth and issue a prescription for empagliflozin without an in-person visit [18].

Minnesota law requires that a valid prescriber-patient relationship exist before a controlled substance is prescribed via telehealth, but empagliflozin is not a controlled substance, which simplifies the pathway. The prescriber must conduct an appropriate clinical evaluation, review relevant labs (HbA1c, eGFR, serum potassium, and a baseline metabolic panel are standard), and document the clinical indication.

Several telehealth platforms licensed in Minnesota offer empagliflozin prescribing, sometimes bundled with the compounded product through a 503A pharmacy partner. Patients should confirm that the prescribing clinician holds an active Minnesota license and that the pharmacy fulfilling the prescription is licensed by the Minnesota Board of Pharmacy.

Follow-up monitoring after starting empagliflozin includes repeat eGFR and urinalysis at 3 months, HbA1c at 3 to 6 months, and assessment for urinary tract infections and genitourinary mycotic infections, the most common adverse effects reported in EMPA-REG OUTCOME (occurring in 4.0% vs. 2.6% for genital mycotic infections in women, empagliflozin vs. placebo) [4].

How to Get the Lowest Price on Jardiance in Minnesota: A Decision Framework

The right approach depends on insurance status, income, and diagnosis. The table below summarizes the primary cost pathways available to Minnesota residents in 2026.

| Patient Situation | Best Option | Estimated Monthly Cost | |---|---|---| | Commercially insured, co-pay under $150 | Use manufacturer savings card | $10/month | | Commercially insured, high deductible | Savings card plus HSA funds | $10 to $150/month | | Minnesota Medicaid (approved PA) | Medicaid formulary co-pay | $1 to $3/month | | Medicare Part D | Part D plan after $2,000 cap | Varies by plan, capped at $2,000/year total | | Uninsured, income below 400% FPL | Boehringer Ingelheim PAP | $0/month | | Uninsured, any income | Compounded 503A empagliflozin | $0 to $150/month | | Uninsured, cost primary concern | GoodRx coupon at preferred pharmacy | $550 to $600/month |

The American Heart Association's 2022 guideline update states: "SGLT2 inhibitors are recommended for patients with HFrEF to reduce hospitalization for HF and cardiovascular mortality, regardless of diabetes status" [19]. That recommendation reinforces the clinical case for pursuing coverage through every available channel rather than discontinuing treatment due to cost.

Monitoring Requirements and Safety Considerations for Minnesota Patients

Starting empagliflozin requires baseline labs regardless of the access pathway used. The minimum workup before a first prescription should include serum creatinine with eGFR, urine albumin-to-creatinine ratio, serum electrolytes, and HbA1c (for diabetes indication) [5].

Empagliflozin is contraindicated in patients with eGFR <20 mL/min/1.73m2 and should not be used for glycemic control when eGFR <45 mL/min/1.73m2, though cardiorenal indications may permit use at lower thresholds per updated FDA labeling [2]. This nuance matters because compounded product prescribers must apply the same contraindication criteria as those prescribing the brand drug.

Euglycemic diabetic ketoacidosis (DKA) is a rare but serious risk. Patients should be counseled to hold empagliflozin 3 days before elective surgery, during prolonged fasting, or during severe illness. The FDA issued a drug safety communication on this topic in 2015 and updated it in 2020 [20].

Volume depletion is a secondary concern, particularly in older adults taking loop diuretics, a common population in the heart failure indication. Monitoring blood pressure and signs of dehydration at the first follow-up visit is standard practice.

Comparing Empagliflozin to Other SGLT2 Inhibitors Available in Minnesota

Three other SGLT2 inhibitors are available in Minnesota with FDA approval: dapagliflozin (Farxiga), canagliflozin (Invokana), and ertugliflozin (Steglatro). Each has a distinct trial evidence base and formulary placement [21].

Dapagliflozin received FDA approval for HFrEF based on the DAPA-HF trial (N=4,744, HR 0.74 to 95% CI 0.65 to 0.85, P<0.001 for the composite endpoint) [22] and for CKD based on DAPA-CKD (N=4,304, HR 0.61 to 95% CI 0.51 to 0.72, P<0.001) [23]. Some Minnesota commercial plans preferentially cover dapagliflozin at a lower tier than empagliflozin, making it a cost-effective alternative when clinical evidence supports either agent.

Canagliflozin's CREDENCE trial (N=4,401) showed a 30% relative risk reduction in the composite of end-stage kidney disease, doubling of serum creatinine, or renal or cardiovascular death (HR 0.70 to 95% CI 0.59 to 0.82, P=0.00001) [24]. The drug carries a boxed warning for lower-limb amputation risk, which influences prescribing decisions.

For patients whose Minnesota insurance plan places empagliflozin on a higher tier than dapagliflozin, switching to dapagliflozin may be clinically appropriate and financially advantageous. A prescriber should review the individual's formulary before writing the initial prescription.

Minnesota-Specific Resources for Empagliflozin Access

Minnesota residents have several state-level resources that may help with drug costs:

The Minnesota Board of Pharmacy (mn.gov/boards/pharmacy) maintains a public license lookup tool for verifying whether a 503A compounding pharmacy is licensed to dispense in Minnesota [15].

The Minnesota Department of Human Services publishes the current Medicaid preferred drug list at mn.gov/dhs, updated quarterly. Checking the current list before submitting a PA ensures the submitted criteria match the current requirements [7].

NeedyMeds.org aggregates patient assistance programs from multiple manufacturers and may identify additional support for Minnesota patients who do not qualify for the Boehringer Ingelheim PAP.

The Minnesota Comprehensive Health Association is the state's high-risk pool and covers empagliflozin under its prescription benefit with PA; premiums and cost-sharing differ from standard commercial plans [25].